
Christopher LiPuma
Mr. LiPuma is a Managing Director in San Francisco in Fortress’s Intellectual Property Group, where he focuses on a wide variety of investment opportunities in connection with intellectual property, life sciences, and academic institutions.
Prior to joining Fortress in 2018, Mr. LiPuma headed business development for Kastle Therapeutics, a private equity-backed biotechnology company acquiring ultra-orphan drugs. Before joining Kastle, he was with OrbiMed Advisors, a life sciences-focused asset management firm. At OrbiMed, he worked on royalty monetizations, direct lending to late development stage and early commercial stage life sciences companies, and several private equity transactions focused on acquiring legacy assets from big pharma. He started his career as an investment banker at Leerink Partners.
Mr. LiPuma holds a B.A. from Hamilton College.
April 10, 2025
Leveraging Intellectual Property (IP) to Access Capital
• How do companies leverage their IP estate to access capital
• A brief overview of the IP valuation process
• Case Study: IP backed term loan
• Case Study: Selling non-core IP
Wednesday March 6, 2024
Why is Venture Debt a Terrible Idea?
- The good, bad, and ugly of venture debt
- When is venture debt a poor plan?
- Using venture debt wisely to fund growth